



In the structure of mortality 
from malignant neoplasms CRC 
ranks 2nd after MN of the respi-
ratory system [1]. The recurrence 
rate of CRC is 30–40 %, which in 
40–50 % occurs in the first few 
years after surgical removal of 
the tumor [2].
The prognosis of CRC largely 
depends on the completeness of 
tumor removal and the stage of 
the disease. At the same time, 
the recurrence and lethal out-
come of patients among each of 
the stages according to the TNM 
system are significantly different. 
Some histological and molecular 
biological features may play an 
important role in determining 
the clinical behaviour of the tu-
mor and the separate prognosis 
of the disease [3]. Thus, cancer 
stroma can play a key role in 
tumor progression, promote 
non-angiogenesis, prevent access 
to immunocompetent cells and 
serve as a diagnostic criterion for 
the course of the disease. How-
ever, reorganization of the CRC 
stroma can both promote and 
limit the aggressive biological be-
haviour of tumor cells [4].
The aim of the research – 
determination of the main mor-
phological features of the CRC 
T3N0-2M0 stroma and search 
for prognostic criteria for their 
recurrence and lethal outcome 
according to the data of surgical 
material and autopsy.
2. Methods
The material of operated 
CRCs and sections of sections of 
patients who died of CRC in the 
Clinical multidisciplinary hos-
pital No. 17 in Kharkiv for the 
period from 2010 to 2020 were 
studied.
The study was approved by the Commission on Bioethics 
of the Kharkiv Medical Academy of Postgraduate Education on 
14.10.21, protocol No. 3.
Selected cases of CRC IIA and IIIB stage, T3N0-1M0 accord-
ing to the TNM system. Group I included primary CRC without 
recurrence. The mean follow-up was 5 years (62.5±16.5 months). 
Group II – primary CRC with recurrence; IIA – with recurrenc-
es within 5 years from the date of tumor removal that did not 
lead to death; IIB – with the appearance of recurrence and lethal 
consequence of the generalization of the tumor process within 
5 years from the moment of removal of the primary tumor. In 
the study groups, adenocarcinomas were selected with the same 
ratio of tumors by differentiation: one case of CRC G1, 14 cases 
of G2, 5 cases of G3 in each group.
The material was paraffin 
blocks of tumors, from which were 
made histological, stained with 
hematoxylin eosin by standard 
methods. Immunohistochem-
ical study was performed using 
monoclonal antibodies to DAKO 
smooth muscle actin alpha. 
The ratio of the stromal com-
ponent to the total area of the 
CRC in the areas of greatest pres-
ence of the tumor stroma was 
investigated. The field of view was 
considered to be a magnification 
of the ×10 microscope lens and in 
the presence of at least one field of 
view with a predominance of the 
stromal component, the tumor 
was classified as CRC with a high 
stromal-parenchymal ratio (SPR).
CRCs were divided into three 
types according to the stroma 
maturity characteristic. Tumors 
with immature stroma had a 
predominance of thin collagen 
fibers, myxomatosis, with high 
cellularity due to active forms 
of fibroblasts. The mature stro-
ma was characterized exclusively 
by coarse collagen fibers, which 
could not be determined due to 
hyalinosis, fibroblasts are absent, 
the stroma resembles scar tis-
sue. RGZ with an intermediate 
type of stroma is characterized 
by intermediate characteristics, 
absence or weak myxomatosis, 
possible non-gross hyalinosis.
An IHC study of the CRC 
stroma for the expression of 
smooth muscle actin alpha was 
performed to differentiate fi-
broblasts from tumor-activat-
ed fibroblasts (TAF). The CRC 
stroma in the reactive change 
zones was conditionally divided 
into one that had a limited TAF 
level and a pronounced TAF lev-
el. Stroma with limited levels of 
TAF was characterized by a few 
myofibroblasts, which were localized more closely near cancer 
complexes and fewer or were absent in areas of reactive stroma 
as they moved away from cancer cells. Stroma with pronounced 
TAF was characterized by diffuse, while TAF were the domi-
nant cells of the connective tissue stroma.
The relationship between the traits was assessed by the non-
parametric Pearson and Spearman χ2-test. p<0.05 was considered 
statistically significant. The analysis of the probability of recurrence 
over a fixed time was assessed by the Kaplan-Meier procedure.
3. Results
CRC with SPR>50 % were in 43.3 % (26/60), respectively in 
56.7 % (34/60) – with SPR≤50 %. It was found that the num-
ber of cases of CRC with a pronounced stromal component 
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the criteria for the prognosis of CRC may be a tumor stro-
ma, which has not been widely used in clinical practice.
The aim was to determine the main morphological features 
of the stroma CRC T3N0-2M0 and search for prognostic 
criteria for their recurrence and lethal outcome according 
to the operating material and autopsy.
Materials and methods. Group I included primary CRC 
without recurrence. The average recurrence-free period was 
5 years (62.5±16.5 months). Group II – primary CRC with 
recurrence; IIA – with recurrences within 5 years from the 
date of tumor removal that did not lead to death; IIB – with 
the appearance of recurrence and lethal consequence of the 
generalization of the tumor process within 5 years from 
the moment of removal of the primary tumor. CRC micro-
preparations made according to the standard method with 
G+E staining were studied; immunohistochemical study 
was performed using monoclonal antibodies to smooth 
muscle actin alpha. 
Results. Stromal-parenchymal ratio>50 % is a prognos-
tic criterion for recurrence (p<0.05) and shorter recur-
rence-free survival (p<0.001) of patients with stage IIA-
IIIB CRC. Immature stroma type CRC stage IIA-IIIB is 
associated with the presence of tumor budding (p<0.001), 
G3 differentiation (p<0.01), shorter recurrence-free sur-
vival (p<0.001); among recurrent CRCs, the immature type 
of stroma is associated with the lethal outcome of patients 
(p<0.05). Expressed levels of tumor-activated fibroblasts are 
one of the criteria for immature CRC stroma (p<0.003), but 
as an independent prognostic criterion has limited prog-
nostic value.
Conclusions. TSR and immature type of stroma are prog-
nostic criteria for recurrence and recurrence period of CRC 
pT3N0-2M0, more typical of tumors of patients with recur-
rence and lethal outcome with the same ratio of tumors by 
differentiation. 
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was higher among recurrent CRC compared with non-re-
current, mainly due to a subgroup of recurrent CRC with a 
fatal consequence of tumor progression (p<0,05) (Table 1). 
Recurrence-free survival (RFS) was 
shown to be lower among CRCs 
with a pronounced stromal compo-
nent (p<0.001) (Fig. 1).
The immature type of stroma 
with myxomatosis was observed 
in 15.0 % (9/60) CRC, was more 
characteristic of recurrent CRC 
(p>0.05) and was associated with 
subgroup IIB – recurrent with a le-
thal outcome (p<0.05), which char-
acterizes this sign as an unfavour-
able prognostic criterion.
There was a statistically sig-
nificant relationship between the 
recurrence period and the type of 
CRC stroma. As can be seen from 
Fig. 1, the RFS of patients with immature stroma type was 
lower (p<0.001), the highest value of RFS was among CRC with 
mature stroma type.
There was a strong correlation between tumor budding (TB) 
and stroma type (r=0.72, p=0.0002), as well as between CRC dif-
ferentiation and stroma type (r=0.56, p=0.004). In areas of TB 
and areas of reduced CRC differentiation with the appearance 
of tumor cell clusters (which characterize G3), the stroma often 
lost its signs of mature and myxomatosis or young active fibro-
blasts appeared. In cases of CRC with TB, the immature type 
of stroma was observed in 32.1 % (9/28), the mature type – in 
25.0 % (7/28), the intermediate type – in 42.9 % (12/28). Among 
CRC with immature type of stroma, G3 differentiation was ob-
served in 66.6 % (6/9), among mature – in 17.6 % (9/51) (p<0.01).
Table 1
Morphological characteristics of the stroma of CRC study groups
Group Features І group, 
n=20
ІІ group, n=40
ІІА, n=20 ІІВ, n=20
SPR>50 % 5 (25.0 %) 8 (40.0 %) 13 (65.0 %)
SPR≤50 % 15 (75.0 %)* 12 (60.0 %) 7 (35.0 %)
Mature type 13 (65.0 %) 11 (55.0 %) 7 (35.0 %)
Intermediate type 5 (25.0) 8 (40.0 %) 7 (35.0 %)
Immature with mixomatosis 2 (10.0 %) 1 (5.0 %) 6 (30.0 %)**
Limited TAF level 13(65.0 %) 9 (45.0 %) 7 (35.0 %)
Expressed level of TAF 7 (35.0 %) 11 (55.0 %) 13 (65.0 %)
Note: * – significant difference from group II, р<0.05; ** – significant 
difference from subgroup IIA, р<0.05
 
It has been shown that the type of CRC stroma is character-
ized by the peculiarity of the distribution and level of TAF, which 
were determined by the positive expression of smooth muscle 
actin alpha. Thus, all CRC cases with immature stroma type had 
a pronounced level of TAF and, accordingly, these two indicators 
had an association (p<0.003), the mature stroma type was associ-
ated with a limited level of TAF (p<0.03), the intermediate stroma 
type was characterized by approximately equal relative number of 
cases with a pronounced and limited level of TAF.
Assessment of TAF levels in invasive areas of the tumor periph-
ery in general complements the characterization of CRC stroma 
types and when considering the impact on the prognosis of CRC 
separately, there was also a tendency to a higher number of cases 
with a pronounced level of TAF among recurrent CRC and recur-
rent with a fatal outcome (p=0.15) and a tendency to a lower term 
RFS among CRC with a pronounced level of TAF (p=0.07) (Fig. 1). 
4. Discussion
Certain CRC factors are important in tumor differentiation, 
cell migration, tumor progression, and the microenviron-
ment and stromal component itself influence the biological 
behaviour, differentiation and dissociation of cancer cells. 
According to some data, type I collagen in the central parts of 
the tumor is a factor of the microenvironment that inhibits the 
process of dedifferentiation [5]. Fibrous stroma can initiate tu-
mor progression, promote non-angiogenesis, prevent access to 
lymphocytes, macrophages and other immunocompetent cells.
In the scientific literature there is a lot of work on the prog-
nostic value of the tumor stroma ratio (tumor cancer ratio) with 
the definition that the tumor stroma ratio of more than 50 % 
characterizes the aggressiveness of CRC and is associated with 
shorter recurrence and overall survival, as well as greater stage T 
and N [6–8]. However, there are opposite data. Thus, according 
to Eriksen A. C. and co-authors [9], low TSR CRC stage II, which 
also did not receive adjuvant PCT, was associated with lower 
recurrence-free survival, overall survival, microsatellite insta-
bility, and increased tumor budding. These data may indicate a 
protective role of the tumor stroma. 
According to our data, evidence and confirmation of the 
fact that the clinical behaviour and consequence of CRC are due 
to the nature of the tumor stroma.
It is also confirmed that the reorganization of cancer stroma 
contributes to the aggressive biological behaviour of tumor cells, 
which may be due to changes in stromal cell types, their molec-
ular biological characteristics, changes in signalling pathways in 
and from stromal cells [4].
One of the key components of reactive cancer stroma is my-
ofibroblasts, or TAF. In addition to ECM production, these cells 
are able to produce lytic enzymes involved in the degradation of 
the basement membranes of tumor glands and promote the for-
mation of the appropriate cancer phenotype with the formation 
of individual clusters of cancer cells, increasing their invasive 
and metastatic activity [10, 11]. The data obtained may indicate 
that TAF is one of the characteristics of the cancerous stroma 
and determine its phenotype. TAFs influence the biological 
behaviour of CRCs, which together with other microenviron-
mental factors determine the clinical behaviour of cancer and 
can serve as prognostic criteria for the disease.
Study limitations. To clarify the role of the stroma in the 
formation of the CRC phenotype and its prognosis, it is nec-
essary to conduct a study using immunohistochemical and 
Fig. 1. 5-year recurrence-free survival (5-year DFS) of patients depending on the area of the 
stromal component (TSR), stroma maturity and TAF level
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molecular genetic markers characterizing both the stromal and 
parenchymal components of the tumor. 
Prospects for further research. It remains relevant to further 
study the CRC stroma at the molecular biological level with the 
determination of its role in the activation of signalling pathways 
and the formation of aggressive clinical behaviour of the tumor.
5. Conclusions
1. Stromal-parenchymal ratio >50 % is a prognostic criteri-
on for recurrence (p<0.05) and shorter recurrence-free survival 
(p<0.001) of patients with stage IIA-IIIB CRC.
2. Immature type of stroma CRC IIA-IIIB stages is associ-
ated with the presence of tumor budding (p<0.001), G3 differ-
entiation (p<0.01), shorter recurrence-free survival (p<0.001); 
among recurrent CRCs, the immature type of stroma is associ-
ated with the lethal outcome of patients (p<0.05).
3. Expressed level of tumor-activated fibroblasts is one of the 
criteria for immature CRC stroma (p<0.003), but as an indepen-
dent prognostic criterion has limited prognostic value.
Conflict of interests
The authors declare there is no conflict of interests.
References
1. Fedorenko, Z. P., Hulak, L. O., Mykhaillvych, Yu. Y., Horokh, Ye. L., Ryzhov, A. Yu., Sumkina, O. V., Kutsenko, L. B. (2020). 
Rak v Ukraini, 2018–2019. Zakhvoriuvanist, smertnist, pokaznyky diialnosti onkolohichnoi sluzhby. Biuleten natsionalnoho 
kantser-reiestru Ukrainy, 21, 101. 
2. Ryuk, J. P., Choi, G.-S., Park, J. S., Kim, H. J., Park, S. Y., Yoon, G. S. et. al. (2014). Predictive factors and the prognosis of recur-
rence of colorectal cancer within 2 years after curative resection. Annals of Surgical Treatment and Research, 86 (3), 143–151. 
doi: http://doi.org/10.4174/astr.2014.86.3.143 
3. Poornakala, S., Prema, N. (2019). A study of morphological prognostic factors in colorectal cancer and survival analysis. In-
dian Journal of Pathology and Microbiology, 62 (1), 36. doi: http://doi.org/10.4103/ijpm.ijpm_91_18 
4. Conklin, M. W., Keely, P. J. (2012). Why the stroma matters in breast cancer: insights into breast cancer patient outcomes through the 
examination of stromal biomarkers. Cell Adhesion & Migration, 6 (3), 249–260. doi: http://doi.org/10.4161/cam.20567 
5. Ueno, H., Jones, A. M., Wilkinson, K. H., Jass, J. R., Talbot, I. C. (2004). Histological categorisation of fibrotic cancer stroma 
in advanced rectal cancer. Gut, 53 (4), 581–586. doi: http://doi.org/10.1136/gut.2003.028365 
6. Hutchins, G. G. A., Treanor, D., Wright, A., Handley, K., Magill, L. et. al. (2017). Intratumoral stromal morphometry predicts 
disease recurrence but not response to 5-fluorouracil-results from the QUASAR trial of colorectal cancer. Histopathology, 
72 (3), 391–404. doi: http://doi.org/10.1111/his.13326 
7. Hynes, S. O., Coleman, H. G., Kelly, P. J., Irwin, S., O’Neill, R. F., Gray, R. T. et. al. (2017). Back to the future: routine mor-
phological assessment of the tumour microenvironment is prognostic in stage II/III colon cancer in a large population-based 
study. Histopathology, 71 (1), 12–26. doi: http://doi.org/10.1111/his.13181 
8. Huijbers, A., Tollenaar, R. A. E. M., v Pelt, G. W., Zeestraten, E. C. M., Dutton, S., McConkey, C. C. et. al. (2013). The pro-
portion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. 
Annals of Oncology, 24 (1), 179–185. doi: http://doi.org/10.1093/annonc/mds246 
9. Eriksen, A. C., Sørensen, F. B., Lindebjerg, J., Hager, H., dePont Christensen, R., Kjær-Frifeldt, S., Hansen, T. F. (2018). The 
prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study. 
International Journal of Colorectal Disease, 33 (8), 1115–1124. doi: http://doi.org/10.1007/s00384-018-3076-9 
10. Martin, M., Pujuguet, P., Martin, F. (1996). Role of Stromal Myofibroblasts Infiltrating Colon Cancer in Tumor Invasion. Pa-
thology – Research and Practice, 192 (7), 712–717. doi: http://doi.org/10.1016/s0344-0338(96)80093-8 
11. Mao, Y., Keller, E. T., Garfield, D. H., Shen, K., Wang, J. (2012). Stromal cells in tumor microenvironment and breast cancer. 
Cancer and Metastasis Reviews, 32 (1-2), 303–315. doi: http://doi.org/10.1007/s10555-012-9415-3 
© The Author(s) 2021
This is an open access article 




How to cite: Yakimenko, A. (2021). The role of tumoral stroma in determining the forecast of recurrence and fatal consequence of stage IIA-
IIIB colorectal cancer. Technology transfer: innovative solutions in medicine, 13–15. doi: https://doi.org/10.21303/2585-6634.2021.002139
